NCT02467127

Brief Summary

To date there are conflicting data concerning a correlation between plasma vitamin D levels and headache. The aim of this study was to evaluate plasma vitamin D levels in patients with headache admitted to the Center of Headache of Pugliese Ciaccio Hospital.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
600

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 26, 2015

Completed
14 days until next milestone

First Posted

Study publicly available on registry

June 9, 2015

Completed
5 months until next milestone

Study Start

First participant enrolled

November 1, 2015

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2017

Completed
1.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2019

Completed
Last Updated

September 25, 2019

Status Verified

September 1, 2019

Enrollment Period

1.8 years

First QC Date

May 26, 2015

Last Update Submit

September 24, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Plasma levels of vitamin D using high performance liquid chromatography

    up to 24 weeks

Secondary Outcomes (1)

  • Headache pain through the Visual Analog Scale (VAS)

    up to 24 weeks

Study Arms (4)

control group

NO INTERVENTION

Patients without headache. No drugs will be administered

Chronic Headache

EXPERIMENTAL

Patients with headache \> 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.

Dietary Supplement: vitamin D supplementation

Chronic headache with drug overuse

EXPERIMENTAL

Patients with headache \> 6 months related to drug treatment, i.e. non steroidal antinflammatory drugs. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.

Dietary Supplement: vitamin D supplementation

Acute Headache

EXPERIMENTAL

Patients without chronic headache but with an history of headache \< 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.

Dietary Supplement: vitamin D supplementation

Interventions

vitamin D supplementationDIETARY_SUPPLEMENT

In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.

Acute HeadacheChronic HeadacheChronic headache with drug overuse

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • acute or chronic headache diagnosed according to the clinical and radiological criteria of the headache Association

You may not qualify if:

  • allergy to drugs,
  • progressive serious medical conditions (such as cancer, AIDS or end-stage renal disease)
  • renal diseases (serum creatinine concentration more than 1.2 times the upper limit of the normal range according to the central laboratory definition reference values)
  • liver dysfunction (serum alanine or aspartate transaminase concentrations more than 1.5 times the upper limit of normal range according to the central laboratory definition reference values)
  • alcohol consumption (\>3 alcoholic beverages daily)
  • substance abuse
  • inability to give written informed consent
  • actual or recent (3-month) treatment with corticosteroids, indomethacin or other antinflammatory drugs.
  • secondary headache

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pugliese Hospital

Catanzaro, 88100, Italy

Location

MeSH Terms

Conditions

Headache

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Luca Gallelli, MD

    University of Catanzaro

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

May 26, 2015

First Posted

June 9, 2015

Study Start

November 1, 2015

Primary Completion

September 1, 2017

Study Completion

April 1, 2019

Last Updated

September 25, 2019

Record last verified: 2019-09

Locations